Communications Medicine · Nov 19, 2026
Metabolic and gut microbiome responses to personalized nutrition during metformin therapy in prediabetes and early‑stage type 2 diabetes: a randomized clinical trial
By Uluturk ZI, Godneva A, Walsh S et al.
Background Metformin is first‑line therapy for type 2 diabetes, yet many individuals do not achieve glycemic targets with metformin alone. We evaluated whether a personalized, algorithm‑based diet targeting postprandial glucose responses improves outcomes compared with a standard healthy diet in individuals initiating metformin. Methods In this randomized controlled trial (ClinicalTrials.gov NCT03558867), 151 adults with prediabetes or early type 2 diabetes were assigned to a personalized diet (PPT, n = 74) or a standard low‑fat, high‑fiber diet (SOC, n = 77), alongside metformin initiation (1.5 g/d). A total of 138 participants who initiated the intervention were included in the intention‑to‑treat analysis (PPT, n = 66; SOC, n = 72). The study had a single enrollment center at the Garvan Institute of Medical Research (Sydney, Australia). The primary outcome was change in glycated hemoglobin at 6 months. Secondary outcomes included continuous glucose monitoring metrics, body composition, liver fat, and cardiometabolic risk markers. Changes in gut microbiome features, including diversity, richness, short‑chain fatty acids, as well as phylum‑ and taxon‑level composition, were assessed as exploratory outcomes. Results Glycated hemoglobin decreased in both groups with no difference between diets. Weight, body composition, liver fat, and cardiometabolic risk markers improved comparably. Glycemic variability decreased slightly more in the personalized diet group. Microbial diversity declined in the PPT group, richness declined in both groups and in the overall cohort, while short‑chain fatty acids declined in the SOC group and overall cohort. Conclusions A personalized diet did not improve glycated hemoglobin relative to a standard healthy diet when initiated alongside metformin. Microbiome analyses suggest a dissociation between declines in microbial features and metabolic improvement, highlighting the complex relationship between gut microbiota and clinical outcomes. The study was registered at ClinicalTrials.gov (Identifier: NCT03558867).